Burk M, Peters U
Clin Pharmacol Ther. 1983 Sep;34(3):331-40. doi: 10.1038/clpt.1983.176.
Disopyramide kinetics were studied in 30 patients with normal to severely impaired renal function (endogenous creatinine clearance 7.6 to 116.9 ml/min/1.73 m2) after intravenous bolus injection. Serum concentration-time curves were fitted to an open two-compartment model. There was close correlation between renal disopyramide clearance and creatinine clearance (r = 0.922). Disopyramide body clearance or elimination rate constant (kel beta) and creatinine clearance did not correlate as closely (r = 0.756 and 0.644). Volume of distribution at steady state and extrarenal clearance of disopyramide both correlated slightly positively with renal function. Disopyramide body clearance and volume of distribution, but not kel beta, were found to be dose dependent. Disopyramide kinetics in renal impairment were not sufficiently predictable from clinical data of the patient because of great interindividual variation in drug disposition and renal and extrarenal elimination. Dosage regimen must therefore be based on individual response and controlled by the clinical effect and estimates of disopyramide serum concentration.
在30例肾功能正常至严重受损(内生肌酐清除率为7.6至116.9 ml/min/1.73 m²)的患者中,静脉推注后研究了丙吡胺的动力学。血清浓度-时间曲线拟合为开放二室模型。肾脏丙吡胺清除率与肌酐清除率之间存在密切相关性(r = 0.922)。丙吡胺体内清除率或消除速率常数(kel beta)与肌酐清除率的相关性不那么密切(r = 0.756和0.644)。稳态分布容积和丙吡胺肾外清除率均与肾功能呈轻度正相关。发现丙吡胺体内清除率和分布容积,但不包括kel beta,是剂量依赖性的。由于药物处置以及肾脏和肾外消除存在很大的个体差异,因此从患者的临床数据中无法充分预测肾功能损害时丙吡胺的动力学。因此,给药方案必须基于个体反应,并通过临床效果和丙吡胺血清浓度的估计来控制。